Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NOTA-SNA002 in Solid Tumors
NCT05989997Phase 1Completed
- Sponsor
- SmartNuclide
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gallium Ga-68 NOTA-SNA002 in solid tumor, sponsored by SmartNuclide. Primary endpoints: Safety of administration (Vital signs) up to 7 days, Laboratory examination up to 7 days and 3 more. Started Nov 2023; status: completed.
02
Drugs
gallium Ga-68 NOTA-SNA002
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05989997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05989997.